Telix Pharmaceuticals Ltd (STU:T3X)
€ 14.31 -0.3 (-2.05%) Market Cap: 4.89 Bil Enterprise Value: 4.84 Bil PE Ratio: 162.08 PB Ratio: 19.98 GF Score: 75/100

Full Year 2023 Telix Pharmaceuticals Ltd Earnings Call Transcript

Feb 22, 2024 / 10:00PM GMT
Operator

Thank you for standing by, and welcome to the Telix Pharmaceuticals Limited FY2023 results call. (Operator Instructions)

I would now like to hand the conference over to Mr. Kyanh Williamson, Senior Vice President, Investor Relations and Corporate Communication. Please go ahead.

Kyahn Williamson
Telix Pharmaceuticals Ltd - Senior Vice President Investor Relations and Corporate Communications

Thank you. Thank you, everybody, for joining our call this morning. You'll have seen that we have launched our annual report and full-year results on the ASX after market closed yesterday. Joining me today on the call is Chris Behrenbruch, Managing Director and Group Chief Executive Officer; Darren Smith, our Group Chief Financial Officer; and Dr. David Cade, our Group's Chief Medical Officer.

If we just turn slide 4, please? Just a few introductory remarks. I mean, it's been a very exciting news to hear at Telix and a lot of hard work, which has led to a lot of achievements. It's been our first full year of commercial sales with reimbursement of Illuccix

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot